Curasight A/S
Hanne Damgaard Jensen is an experienced pharmaceutical executive with a strong background in drug development and regulatory affairs. As the CEO and Founder of ROS Therapeutics since April 2018, Hanne leads initiatives to innovate treatments for children with juvenile arthritis through an oral methotrexate product. In addition, Hanne serves as Chief Development Officer at Curasight and has held various senior roles at companies such as AimVion A/S, Azanta A/S, Santaris Pharma, Genmab, Novo Nordisk, and IOLAB. Notable achievements include the successful registration of products in Denmark and the establishment of compassionate use programs for oncology treatments. Hanne holds an MBA from Copenhagen Business School and an M.Sc. in Pharmacy from Danmarks Farmaceutiske Universitet.
This person is not in any teams
Curasight A/S
Curasight is a biotech company focused on addressing the need for improved diagnosis and treatment of several cancer indications. The Company has developed a highly specific PET (Positron emission tomography) imaging ligand, uTRACE®, targeting the receptor uPAR, which is a biomarker only expressed in cancer. uTRACE® will become a game-changer inthe diagnosis and treatment of cancer patients.In addition, with the promising results obtained within diagnostics Curasight will also pursues uPAR targeted radionuclide therapy using the uTREAT® ligand. As PET imaging and radionuclide therapy is based on the same uPAR binding peptide, a uTRACE® scan can precisely predict where subsequent targeted radiation therapy will be delivered. uTRACE® covers the diagnostic path and uTREAT® covers the therapy. This will be the new management and treatment of cancer patients in the future.